Literature DB >> 10947042

Influence of HLA matching and associated factors on aortic valve homograft function.

R Dignan1, M O'Brien, P Hogan, J Passage, F Stephens, A Thornton, S Harrocks.   

Abstract

BACKGROUND AND AIM OF THE STUDY: Evidence suggests that the implanted aortic valve homograft suffers eventual loss of function due to early donor-specific antibody and T cell-mediated responses to human leukocyte antigens (HLA). The association between rejection/dysfunction and donor/recipient HLA mismatch for vascularized organ homografts has not been revealed for aortic valve homografts. An aortic valve homograft recipient cohort was studied to determine whether HLA mismatch and associated factors predicted homograft dysfunction.
METHODS: Both donor and recipient HLA type was obtained for 162 recipients of cryopreserved aortic valve homografts between 1986 and 1998. Structural deterioration of the homograft was defined by echocardiography as at least moderate aortic stenosis or regurgitation. Patients' records were searched for postoperative fever, ABO blood type disparity, and other associated factors. HLA class 1 (A and B antigens) were typed serologically, and HLA class 2 (DR antigens) by molecular genotyping. Associations were analyzed using chi-square tests and Kaplan-Meier curves of freedom from structural deterioration in all patients, and in those with > or =5 years of follow up. Cox regression was used to determine independent predictors of structural deterioration.
RESULTS: Class 2 antigen mismatch had a significant association (p = 0.04) with decrease in cryopreserved aortic valve homograft freedom from structural deterioration in patients with long-term follow up (> or =5 years). In addition, there was an important difference in frequency of postoperative fever in recipients with two DR mismatches (31.2%), and in those with no or one DR mismatch (16.9%; p = 0.051). Significant associations were not found between homograft dysfunction and HLA mismatch at the class-1 loci. Young age at operation and short time (<4 h) between homograft procurement and cryopreservation were associated with an increase in structural deterioration.
CONCLUSION: The association between aortic valve homograft dysfunction and HLA DR mismatch suggests that elements of the anti-donor immune response penetrate and damage the homograft. A similar link to postoperative fever indicates that immune stimulation may be an early event. Further investigation will reveal the exact pathways by which this occurs and by which therapy (immunosuppression of the recipient, genetic engineering of the donor graft, or other techniques) this recipient anti-donor response can be modified.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10947042

Source DB:  PubMed          Journal:  J Heart Valve Dis        ISSN: 0966-8519


  5 in total

1.  Decellularized Cryopreserved Allografts as Off-the-Shelf Allogeneic Alternative for Heart Valve Replacement: In Vitro Assessment Before Clinical Translation.

Authors:  Laura Iop; Adolfo Paolin; Paola Aguiari; Diletta Trojan; Elisa Cogliati; Gino Gerosa
Journal:  J Cardiovasc Transl Res       Date:  2017-03-09       Impact factor: 4.132

2.  Homografts in aortic position: does blood group incompatibility have an impact on patient outcomes?

Authors:  Ferdinand Vogt; Bernhard Michael Böll; Anne-Laure Boulesteix; Eckehard Kilian; Giuseppe Santarpino; Bruno Reichart; Christoph Schmitz
Journal:  Interact Cardiovasc Thorac Surg       Date:  2013-02-06

Review 3.  Can Heart Valve Decellularization Be Standardized? A Review of the Parameters Used for the Quality Control of Decellularization Processes.

Authors:  F Naso; A Gandaglia
Journal:  Front Bioeng Biotechnol       Date:  2022-02-17

Review 4.  Guided tissue regeneration in heart valve replacement: from preclinical research to first-in-human trials.

Authors:  L Iop; G Gerosa
Journal:  Biomed Res Int       Date:  2015-10-01       Impact factor: 3.411

Review 5.  Residual Bioprosthetic Valve Immunogenicity: Forgotten, Not Lost.

Authors:  Paul Human; Deon Bezuidenhout; Elena Aikawa; Peter Zilla
Journal:  Front Cardiovasc Med       Date:  2022-01-04
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.